Clinical Trial Update: Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating isatuximab, dexamethasone, and lenalidomide in ultra-frail patients with multiple myeloma and plasma cell leukemia, currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Revlimid (lenalidomide)
• SARCLISA (isatuximab)

Snippet

Sponsor: University of Utah | Conditions: Multiple Myeloma, Plasma Cell Leukemia | Phase 2 | Status: RECRUITING